Eureka Therapeutics
Eureka Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company headquartered in Emeryville, California, developing T-cell therapies for solid tumors and hematologic malignancies. The company was founded by Dr. Cheng Liu and is built on two proprietary platforms: E-ALPHA, a high-throughput human antibody discovery engine used to find binders against cancer-specific targets, and ARTEMIS, an engineered T-cell receptor platform (AbTCR) designed to deliver CAR-T-level potency with a reduced cytokine-release profile. Its clinical programs include ET140203 (ARYA-1 in adults, ARYA-2 in pediatrics) and ECT204 (ARYA-3) in advanced liver cancer, alongside a GPC2 ARTEMIS T-cell program for neuroblastoma licensed from the National Cancer Institute. Eureka publishes a corporate website, pipeline and technology overviews, a press-release archive with an RSS feed, and patient-facing trial information; as of this profile it publishes no public developer portal, API documentation, or machine-readable API contract.
Eureka Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Cell Therapy.
Eureka Therapeutics’ developer surface includes engineering blog, support, and 12 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 6
The organization behind the API
Other 3
Properties that don't map to a standard resource type